N/A
Completed N=3,006
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Source: ClinicalTrials.gov NCT01396434 ↗Enrolled (actual)
3,006
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 68; 5; 0; 1 participants
Summary
Prevenar 13 is safe for administration to Filipinos.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
68; 5; 0; 1; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
Patients prescribed with the vaccine
Exclusion Criteria
Patients with hypersensitivity to the vaccine
Data sourced from ClinicalTrials.gov (NCT01396434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.